Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21FN2O2 |
| Molecular Weight | 328.3806 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCO\N=C(\C=C\C1=CC=C(O)C=C1)C2=CC=CC=C2F
InChI
InChIKey=VAIOZOCLKVMIMN-PRJWTAEASA-N
InChI=1S/C19H21FN2O2/c1-22(2)13-14-24-21-19(17-5-3-4-6-18(17)20)12-9-15-7-10-16(23)11-8-15/h3-12,23H,13-14H2,1-2H3/b12-9+,21-19-
| Molecular Formula | C19H21FN2O2 |
| Molecular Weight | 328.3806 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Optical Activity | NONE |
Eplivanserin (SR 46349) is an antagonist of serotonin 2A receptor. Eplivanserin was previously in development by Sanofi-aventis in an effort to educate the public regarding this new mechanism of action for sleep aids. Eplivanserin was reviewed by the FDA as a potential treatment for patients with chronic insomnia, but the FDA requested additional information regarding benefit-risk and development of the drug has been discontinued.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00253968
Phase III study: 5 mg/day for 12 weeks
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:27 GMT 2025
by
admin
on
Mon Mar 31 18:05:27 GMT 2025
|
| Record UNII |
3CO94WO6DJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66885
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135456190
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
130579-75-8
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL257704
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
7771
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
DTXSID601028413
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
EPLIVANSERIN
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
100000093074
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
SUB30142
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
WW-96
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
3CO94WO6DJ
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
C65517
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY | |||
|
DB12177
Created by
admin on Mon Mar 31 18:05:27 GMT 2025 , Edited by admin on Mon Mar 31 18:05:27 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET->INVERSE AGONIST |
Experimental drug for the treatment of insomnia.
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |